Summary
• Carisma Therapeutics’ shares fell 13.8% to $0.056 amid delisting news from Nasdaq.
• The company announced voluntary delisting and deregistration on December 5, following noncompliance issues.
• Year-to-date decline is 88.3%, with trading volume significantly below averages, signaling low investor confidence.
Carisma Therapeutics, Inc. (CARM) is seeing its shares tumble approximately 13.8% in intraday trading, now priced at $0.056. This slide comes after the company’s recent announcement regarding delisting from the Nasdaq, marking a significant corporate development.
Delisting and Deregistration Announcement
On December 5, 2025, Carisma Therapeutics disclosed that its Board of Directors has approved the voluntary delisting of its common stock from the Nasdaq Stock Market and the associated deregistration of its common stock. This move aims to suspend and ultimately terminate the company’s reporting obligations under the Securities and Exchange Act of 1934. The decision follows a delist determination letter issued by Nasdaq on October 9, 2025, due to noncompliance with listing requirements. The stock was subsequently suspended from trading on Nasdaq on October 13, 2025.
Market Performance and Technical Overview
As shares trade at $0.056, Carisma is grappling with significant negative pressure, reflected in a staggering 88.3% decline year-to-date and over 68% drop this week alone. The stock’s RSI stands at 29.98, indicating oversold conditions. Additionally, it has been underperforming against its 20-, 50-, and 200-day SMAs, with deviations of -44.2%, -47.2%, and -55.3% respectively.
Volume for the day has been recorded at 196,465, well below its average volume of 373,315 over the past 10 days and 841,983 over the last three months. The steep decline in price and the deterioration in trading metrics raises concerns about investor confidence and market interest.
Historical Context and Future Outlook
While Carisma’s delisting and deregistration move is recent, the underlying issues leading to this decision stretch back, culminating in major stock price volatility. The negative growth trend highlights significant challenges within the company, which may impact its financial health and operational strategy moving forward.
With a stock currently rated as a “Hold” by analysts, investors are navigating a period of high uncertainty. As Carisma adapts to its new trading circumstances, further developments and strategic choices will be closely watched by market participants.